Literature DB >> 9833802

Physiologic effects of steroid hormones and postmenopausal hormone replacement on the female breast and breast cancer risk.

I A Mustafa1, K I Bland.   

Abstract

Most data demonstrate that breast cancer is hormonally influenced. For the woman with no history of breast cancer, the benefits of HRT may outweigh the risks. Although it remains the standard of care to discourage hormone use in patients who have had breast cancer, future studies may result in a change of this standard. There needs to be more research into these complex hormonal interactions so that we will have a better understanding of the true risks and benefits when we attempt to advise our patients regarding the best treatment regimens for them.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9833802      PMCID: PMC1191569          DOI: 10.1097/00000658-199811000-00003

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  102 in total

1.  Age-specific differences in the relationship between oral contraceptive use and breast cancer.

Authors:  P A Wingo; N C Lee; H W Ory; V Beral; H B Peterson; P Rhodes
Journal:  Obstet Gynecol       Date:  1991-08       Impact factor: 7.661

2.  Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.

Authors:  M J Stampfer; G A Colditz
Journal:  Prev Med       Date:  1991-01       Impact factor: 4.018

3.  A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.

Authors:  K K Steinberg; S B Thacker; S J Smith; D F Stroup; M M Zack; W D Flanders; R L Berkelman
Journal:  JAMA       Date:  1991-04-17       Impact factor: 56.272

Review 4.  Epidemiologic evidence for the increased cell proliferation model of carcinogenesis.

Authors:  S Preston-Martin; M C Pike; R K Ross; B E Henderson
Journal:  Prog Clin Biol Res       Date:  1991

5.  Pre-existing fractures and bone mass predict vertebral fracture incidence in women.

Authors:  P D Ross; J W Davis; R S Epstein; R D Wasnich
Journal:  Ann Intern Med       Date:  1991-06-01       Impact factor: 25.391

6.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.

Authors:  R R Love; R B Mazess; H S Barden; S Epstein; P A Newcomb; V C Jordan; P P Carbone; D L DeMets
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

7.  Identification of heregulin, a specific activator of p185erbB2.

Authors:  W E Holmes; M X Sliwkowski; R W Akita; W J Henzel; J Lee; J W Park; D Yansura; N Abadi; H Raab; G D Lewis
Journal:  Science       Date:  1992-05-22       Impact factor: 47.728

8.  Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells.

Authors:  E Peles; S S Bacus; R A Koski; H S Lu; D Wen; S G Ogden; R B Levy; Y Yarden
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

9.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study.

Authors:  M J Stampfer; G A Colditz; W C Willett; J E Manson; B Rosner; F E Speizer; C H Hennekens
Journal:  N Engl J Med       Date:  1991-09-12       Impact factor: 91.245

10.  Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.

Authors:  C C McDonald; H J Stewart
Journal:  BMJ       Date:  1991-08-24
View more
  3 in total

1.  Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-beta1 in breast cancer cell lines.

Authors:  Trevor A Petrel; Robert W Brueggemeier
Journal:  J Cell Biochem       Date:  2003-01-01       Impact factor: 4.429

Review 2.  Epidemiology of endocrine-related risk factors for breast cancer.

Authors:  Leslie Bernstein
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

Review 3.  Pesticides and breast cancer risk: a review of DDT, DDE, and dieldrin.

Authors:  S M Snedeker
Journal:  Environ Health Perspect       Date:  2001-03       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.